What question did this study set out to answer?

This research aims to evaluate the efficacy of the PFL regimen for treating severe liver crisis in metastatic breast cancer and to identify prognostic factors for treatment response.

January 10, 2026Cancer Research and Treatment0 citationsOpen Access

Platinum and 5-FU Salvage Therapy for Severe Liver Crisis in Metastatic Breast Cancer: Efficacy and Analysis of Prognostic Factors

IHI-Wei HoNational Yang Ming Chiao Tung University JLJiun-I. LaiNational Yang Ming Chiao Tung University CLChun-Yu LiuTaipei Veterans General Hospital

Key Result

The PFL regimen effectively improved survival outcomes in metastatic breast cancer patients with severe liver crisis and hyperbilirubinemia, with a FIB-4 score <9.1 predicting better responses.

Key Points

This research aims to evaluate the efficacy of the PFL regimen for treating severe liver crisis in metastatic breast cancer and to identify prognostic factors for treatment response.
Evaluated the PFL regimen in metastatic breast cancer patients with severe liver crisis and hyperbilirubinemia.
Assessed the FIB-4 score as a potential prognostic factor for treatment response.
Analyzed survival outcomes related to bilirubin response.
The PFL regimen was effective in reducing bilirubin levels in patients with severe liver crisis.
A FIB-4 score of less than 9.1 was associated with better bilirubin response.
Patients with lower FIB-4 scores demonstrated improved survival outcomes.

Structured PICO

Does the PFL regimen improve overall survival and progression-free survival in metastatic breast cancer patients with severe liver crisis?

Population

44 female patients with metastatic breast cancer (MBC) presenting with severe liver visceral crisis (total bilirubin ≥ 3 mg/dL), mean age 54.2 years, 100% female.

Intervention

PFL regimen (carboplatin AUC=2 or cisplatin 50mg/m² on Day 1, 5-fluorouracil 2400mg/m² as a 46-hour continuous infusion, and folinic acid 200 mg/m² prior to 5-FU) administered every two weeks.

Outcome

Overall survival (OS) and progression-free survival (PFS)hard clinical

The PFL regimen is a viable rescue strategy for metastatic breast cancer patients in severe liver crisis, with a FIB-4 score <9.1 predicting better bilirubin response and survival.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

The PFL regimen is effective in MBC patients with severe liver crisis with hyperbilirubinemia. A FIB-4 score <9.1 may serve as a potential prognostic factor for bilirubin response and is associated with improved survival outcomes.

Ask AI

Helpful

Bookmark

View Full Paper